Microvascular Alterations in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder associated with continual decline in cognition and ability to perform routine functions such as remembering familiar places or understanding speech. For decades, amyloid beta (Aβ) was viewed as the driver of AD, triggering neurodegenerative processes such as inflammation and formation of neurofibrillary tangles (NFTs). This approach has not yielded therapeutics that cure the disease or significant improvements in long-term cognition through removal of plaques and Aβ oligomers. Some researchers propose alternate mechanisms that drive AD or act in conjunction with amyloid to promote neurodegeneration. This review summarizes the status of AD research and examines research directions including and beyond Aβ, such as tau, inflammation, and protein clearance mechanisms. The effect of aging on microvasculature is highlighted, including its contribution to reduced blood flow that impairs cognition. Microvascular alterations observed in AD are outlined, emphasizing imaging studies of capillary malfunction. The review concludes with a discussion of two therapies to protect tissue without directly targeting Aβ for removal: (1) administration of growth factors to promote vascular recovery in AD; (2) inhibiting activity of a calcium-permeable ion channels to reduce microglial activation and restore cerebral vascular function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Montagne, A., Nikolakopoulou, A. M., Zhao, Z., Sagare, A. P., Si, G., Lazic, D., Barnes, S. R., Daianu, M., Ramanathan, A., Go, A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4482 · Cited by 344 · cited 1×
“Flow decreases may be induced by atherosclerosis (Gupta and Iadecola, 2015), while BBB damage could be caused by pericyte degeneration (Miners et al., 2018; Montagne et al., 2018; Wåhlin and Nyberg, 2019).”
BackgroundRetractedThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824 · cited 3×
“This CSF-ISF mixture, via bulk flow or diffusion, travels through the tissue and is eliminated along paravascular spaces surrounding veins (Iliff et al., 2012; Reeves et al., 2020).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Delivery of a single growth factor, such as VEGF, risks producing vessel networks prone to leaks or hemorrhage (Yancopoulos et al., 2000).”
BackgroundImmunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 1×
“Aducanumab, a human monoclonal antibody directed against Aβ, reduced soluble and insoluble parenchymal Aβ in Tg2576 AD mice, while reducing Aβ in humans and slowing clinical decline (Sevigny et al., 2016).”
BackgroundBlood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312 · cited 1×
“The cells types of the NVU include endothelial cells, pericytes, smooth muscle cells (arterial and venous), astrocytes, microglia, oligodendrocytes, and neurons (Sweeney et al., 2019).”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“Late onset AD is characterized by impaired Aβ clearance (Mawuenyega et al., 2010).”
BackgroundInitiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Cited by
Cummings, J. L., Atri, A., Feldman, H. H., Hansson, O., Sano, M., Knop, F. K., Johannsen, P., León, T., & Scheltens, P. (2025) · Alzheimer's Research & Therapy · doi:10.1186/s13195-024-01666-7 · Cited by 168
Hypoxia compromises the mitochondrial metabolism of Alzheimer’s disease microglia via HIF1
March-Diaz, R., Lara-Ureña, N., Romero-Molina, C., Heras-Garvin, A., Ortega-de San Luis, C., Alvarez-Vergara, M. I., Sanchez-Garcia, M. A., Sanchez-Mejias, E., Davila, J. C., Rosales-Nieves, A. E., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00054-2 · Cited by 125
Cummings, J. L., Atri, A., Sano, M., Zetterberg, H., Scheltens, P., Knop, F. K., Johannsen, P., Wichmann, C. A., Abschneider, R. M., Leon, T., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00459-9 · Cited by 110
Metadata
- Authors
- Steinman, J., Sun, H.-S., & Feng, Z.-P.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2021-01-18
- Volume
- 14
- Pages
- 618986-618986
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W3123867917
- Cited by
- 81
- References
- 93
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microvascular Alterations in Alzheimer's Disease. https://app.cochat.ai/papers/10.3389/fncel.2020.618986
- The paper
- Steinman, J., Sun, H.-S., & Feng, Z.-P. (2021). Microvascular Alterations in Alzheimer's Disease. Frontiers in Cellular Neuroscience. https://doi.org/10.3389/fncel.2020.618986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.